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As alarming as the threat of AIDS is in the United States,' the scope of the
epidemic in this country is dwarfed by its magnitude overseas. 2 Worldwide, as
of early 1994, more than 22 million people had been infected by the human
immunodeficiency virus (HIV), and at least 6.8 million had developed full-blown
AIDS. 3 An additional 6,000 people are infected every day, approximately 80
percent of them in the developing world.4 By the turn of the century the death
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1. In North America, excluding Spanish-speaking countries, there were 1,138,000 accumu-
lated HIV cases as of January 1, 1994, and 327,000 cases of AIDS. David Perlman, World AIDS
Experts Gather in Asia-Current Hot Spot, S.F. CHRON., Aug. 6, 1994, at A3. The incidence
of new infections in the United States has declined slightly. New AIDS Cases Decline 7% in
U.S., S.F. CHRON., Apr. 19, 1996, at A2.
2. Id.; see also Ramon G. McLeod, AIDS Taking Heavier Toll Around World, S.F. CHRON.,
Apr. 29, 1994, at Al, A19.
3. Perlman, supra note 1, at A3. Others report over 17 million HIV infections and over 4 million
cases of AIDS. Id. "Over 90% of all HIV infections worldwide are acquired through heterosexual
intercourse." HIV Vaccines-Accelerating the Development of Preventive HIV Vaccines for the
World, Summary Report and Recommendations of an International Ad Hoc Scientific Committee
3 (sponsored by The Rockefeller Foundation and the Fondation Mdrieux, Paris, France, Oct. 27-28,
1994) [hereinafter Summary Report]. Women now represent 50% of all new HIV infections, Women
Fastest-Growing Group Contracting HIV, S.F. CHRON., Feb. 9, 1995, at A16, and more than
1.5 million children have the disease. Charles Petit, AIDS Rife in Asia, Experts Say, S.F. CHRON.,
Feb. 21, 1995, at A3.
4, Sven Sandstrom, Global AIDS Strategy Is Not Doing the Job, S.F. CHRON., Dec. 1, 1994,
at A23. By the end of this decade, 95 % of HIV infections will occur in developing countries. World
AIDS Day, S.F. CHRON., Dec. 1, 1994, at A22. "If not another single African became infected,
AIDS deaths in the region over the next decade would still exceed 8.3 million-tripling the current
rate. In some African cities, the infection rate is as high as 1 in 3." Id. Approximately 25% of
Uganda's population of 16 million have the AIDS virus. Uganda's Harsh AIDS Message, BoSTON
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toll across the globe is estimated to be about 2 million people every year.' In
terms of death and catastrophic social disruption, the pandemic will match the
worst wars of this century,6 potentially claiming as many as 121 million lives
by the year 2020.'
These grim facts and predictions demonstrate the obvious need for a cure
and for a preventive or therapeutic vaccine.8 But the virus presents formidable
obstacles toward the achievement of these goals. It mutates rapidly and exists
in thousands of forms. 9 Distinct viral groups are found in different regions of
the world that vary genetically from each other. l Thus, a vaccine that targets
the viral strain in North America might be ineffective, or less effective, in South-
east Asia or Africa; moreover, it might work today but not tomorrow against
new variations of the virus."'
Despite these obstacles, efforts to create a vaccine are underway. Two "first
generation" vaccines, which employ a specific component of the HIV coating,
initially appeared promising, but the AIDS Research Advisory Committee at the
National Institutes of Health barred them from large-scale testing in the United
GLOBE, July 22, 1993, at 10. By the year 2000, however, the majority of infections will occur in
Asia. Sandstrom, supra, at A23. Perlman, supra note 1, at A3. It is estimated that 2 to 4 million
of Thailand's 60 million citizens will be HIV positive by the end of this millennium, at an estimated
cost of 10 % of the nation's current 90 billion gross domestic product. Martha Irvine, Thai Businesses
Join Fight Against AIDS Epidemic, S.F. CHRON., May 10, 1995, at A16. India now leads the world
in people infected with the AIDS virus. Lawrence K. Altman, India Quickly Leads in HIV Cases,
AIDS Meeting Hears, N.Y. TiMEs, July 8, 1996, at A3. Experts predict that 1 million people in
India will have AIDS and 5 million will be HIV positive by the year 2000; by 2010, India could
have 30 million HIV infected citizens, putting overwhelming pressure on government health facilities
and creating millions of orphans. John Ward Anderson, India Fast Becoming World's Scariest AIDS
Flash Point, S.F. CHRON, Sept. 2, 1995, at C16.
5. Sandstrom, supra note 4, at A23.
6. David Perlman, AIDS Conference Winds Down-Little to Rejoice About, S.F. CHRON., Aug.
12, 1994, at A17.
7. McLeod, supra note 2, at A19. Life expectancies in many countries will be reduced dramati-
cally, e.g., by approximately 28 years in Kenya, 25 years in Tanzania, 33 years in Zambia, and 30
years in Thailand. Id.
8. A therapeutic vaccine stops the progression of a disease once an infection is already present,
e.g., the vaccination for rabies, whereas a preventive vaccination prevents a disease from occurring
at all, e.g., the vaccination for polio. See David Perlman, New Reports of Progress on Post-AIDS
Therapies, S.F. CHRON., July 23, 1992, at Al.
9. Vaccine Guards Monkeys from Simian AIDS, S.F. CHRON., Jan. 24, 1992, at A12; see also
Larry Gostin, Vaccination for AIDS: Legal and Ethical Challenges From the Test Tube, To the
Human Subject, Through to the Marketplace, 2 AIDS & PU. POL'Y J. 9, 10 (1987); Sabin Russell,
Rare HIV Strain Eludes Screening Tests, S.F. CHRON., June 8, 1994, at A2.
10. "Huge variation in the genetic sequence of HIV- 1 envelope genes has led to their classification
into more than six genetic groups (clades) worldwide. Within each clade, there is considerable viral
variation as well." AIDS ACTION FOUNDATION, HIV PREVENTIVE VACCINES: SOCIAL, ETHICAL
AND POLITICAL CONSIDERATIONS FOR DOMESTIC EFFICACY TRIALS 5 (1994); see also Summary
Report, supra note 3, at 9.
11. AIDS ACTION FOUNDATION, supra note 10; Summary Report, supra note 3, at 5.
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States.12 Many "next-generation" vaccines are currently being evaluated in pre-
liminary trials.' 3 Nevertheless, a workable vaccine still appears to be far in the
future. 14 In addition to the enormous technical difficulties involved, the costs of
development are high, and, particularly in the developing world, the return on
investment is low.'" Companies are abandoning the effort.
16
The development of a vaccine is further inhibited by the fear of tort liability
should a recipient, for any reason, claim an adverse reaction.17 "From a manufac-
turer's perspective, the single most critical issue will doubtless be the manufactur-
er's liability for personal injuries associated with the vaccine. . . . [N]o sane
manufacturer would be or should be willing to market such a vaccine without
some form of tort relief. The liability exposure is too great in view of the scanty
profits. '"'8 This concern is doubtless stimulated by the litigious zeal of the U.S.
citizenry, 9 but it could apply also to liability exposure in the rest of the world,
12. AIDS ACTION FOUNDATION, supra note 10, at 4; see also Sabin Russell, U.S. Stalls Tests
of AIDS Vaccines Made by Bay Firms, S.F. CHRON., June 18, 1994, at A3; David Perlman, Contro-
versy Over Testing of Existing AIDS Vaccines, S.F. CHRON., Aug. 10, 1994, at A4. But Dr. Michael
Merson, Director of the World Health Organization's Global Program on AIDS, said that, pending
government approval in the countries involved, large-scale tests of the vaccines could take place in
Brazil and Uganda. Trials are also planned in Thailand. Id.
13. AIDS ACTION FOUNDATION, supra note 10, at 6. The next generation vaccines involve live
vector envelope subunits, such as a bird or mouse virus, to carry isolated components of HIV or
whole killed virus vaccines (which are widely employed to combat other diseases). Id. at 4; see
also David Perlman, Promising Steps Toward AIDS Vaccine, S.F. CHRON., Aug. 2, 1994, at 1. A
nonvirulent strain of the HIV virus has been discovered with a missing genetic segment that might
be the model for an attenuated virus vaccine. Sign of Hope for Developing AIDS Vaccine, S.F.
CHRON., Nov. 11, 1995, at Al, A21. However, further research on a once promising vaccine has
recently been halted, Highly Touted AIDS Vaccine Found Wanting, S.F. CHRON., Apr. 19, 1996,
at A2, and while strong hope has been expressed, there are mixed reactions to reports about the
efficacy of new combination drug therapies. Lawrence K. Altman, At AIDS Meeting, Experts Find
an Uneasy Mix of Hope and Fear, N.Y. TIMES, July 9, 1996, at C5.
14. Lisa M. Krieger, Doctors Offer Hope, No Cure, at AIDS Conference in Japan, S.F. EXAM.,
Aug. 7, 1994, at 1; David Perlman, Crown Prince Greets AIDS Scientists, S.F. CHRON., Aug. 8,
1994, at A3.
15. Donald P. Francis & Donald Kennedy, A Private-Sector AIDS Vaccine? Don't Hold Your
Breath, WASH. POST, July 19, 1994, at A17. Development costs for a new drug can reach $90-95
million, Nancy E. Pirt, Regulation of the Export of Pharmaceuticals to Developing Countries, 25
DuQ. L. REv. 255, 269 (1987). The developing world, which contains three quarters of the world's
population, accounts for only 20% of drug sales worldwide because of low per capita income. Id.
at 271 (citing a study by the Office of Industry Assessment of the International Trade Administration,
U.S. Department of Commerce).
16. David Scondras & Dr. Paul Epstein, Leadership Needed in Development of an AIDS Vaccine,
BOSTON GLOBE, Aug. 5, 1994, at 19.
17. OFFICE OF TECHNOLOGY ASSESSMENT, LIABILITY IS ONE OF MANY DETERRANTS TO AIDS
VACCINE DEVELOPMENT (1995). Francis & Kennedy, supra note 15, at A17. I have written about
the principal liability concerns of drug companies-the litigation explosion, punitive damages, and
strict products liability-and the need for a statute similar to the National Childhood Vaccine Injury
Act to encourage vaccine development. John P. Wilson, The Resolution of Legal Impediments to
the Manufacture and Administration of an AIDS Vaccine, 34 SANTA CLARA L. REV. 495 (1994).
18. Robert P. Charrow, An AIDS Vaccine: It May Take an Act of Congress, 6 J. NIH RES. 84
(1994); see also Summary Report, supra note 3, at 6.
19. Charrow, supra note 18, at 54.
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the area of greatest need. For once a technique to develop a successful vaccine
is mastered in the United States, it should be replicable elsewhere with different
viral groupings. As the recent, and possibly ongoing, silicone gel breast implant
litigation makes clear 2 -or the less recent representation of hapless shantytown
inhabitants following the toxic gas explosion at the Union Carbide chemical
facility in Bhopal, India2'-American lawyers willingly bring suits in American
courts on behalf of foreign claimants who are injured overseas.
This article explores the liability exposure of U.S. pharmaceutical corporations
that might some day market an AIDS vaccine in the developing world and incur
potential liability for injury. Why would suit in the United States be advantageous,
and in what ways could a company protect itself? If a U. S. court retains jurisdiction,
how would damages be measured? If injury is widespread yet suits are dismissed
on forum non conveniens grounds to a nonexistent remedy in a foreign country,
what are the implications for both business and U.S. foreign policy relations? Is
there a middle position that would permit some compensation, based on verifiable
injury, without incurring the potentially staggering costs of the U.S. tort system?
I. Administration of a Vaccine
Drugs, including vaccines, that are developed in the United States may be
exported to other countries after approval by the Food and Drug Administration.22
Unapproved drugs in the domestic approval process may also be exported, but
only to certain countries that have well-developed, qualified testing processes
and have already approved the drugs for safety and efficacy.23 The purpose of
this control is to limit the dumping of dangerous, untested drugs in countries
without sophisticated approval processes and, concomitantly, to encourage the
development of safe and useful drugs to combat diseases in such countries.24
Ideally, an AIDS vaccine would be administered orally, would be inexpensive,
20. Lindsay v. Dow Coming Corp., Final Order and Judgment and Opinion (Approval of Settle-
ment), Civ. Action No. CV 94-P-11558-S (N.D. Ala. 1994); see also Aguinda et al. v. Texaco Inc.,
93 CIV 7527 (VLB) (S.D.N.Y. Nov. 3, 1993) (involving a suit against Texaco for the allegedly
deliberate contamination of native Indian land during the extraction of oil in Ecuador's rain forest).
Laurie Goering, Texaco Sued over Forest in Ecuador, BOSTON GLOBE, July 3, 1996, at 2.
21. JAMIE CASSELS, THE UNCERTAIN PROMISE OF LAW: LESSONS FROM BHOPAL 115-17 (1993);
In re Union Carbide Corp. Gas Plant Disaster, 634 F. Supp. 842, 844 (S.D.N.Y. 1986), aff'd, 809
F.2d 195, 197 (2d Cir.), cert denied, 484 U.S. 871 (1987).
22. Pirt, supra note 15, at 280; James C. Grant, Note, The Impact of the Drug Export Amendments
Act of 1986 on Foreign Tort Victims, 21 VAND. J. TRANSNAT'L L. 809, 814 (1988).
23. The Drug Export Amendments Act of 1986, 21 U.S.C. § 382 (Supp. IV 1986), amending
the Federal Food, Drug and Cosmetics Act, 21 U.S.C. §§ 301-332 (1982 & Supp. IV 1986). The
listed countries are set forth at 21 U.S.C. § 382(b)(4)(A) (Supp. IV 1986). See also Pirt, supra note
15, at 282; Grant, supra note 22, at 812, 813. An immediate prohibition will result if an importer
in an approved country reexports to an unapproved country or if a drug is exported directly to an
unapproved country. Id. at 818. There is, however, no enforcement mechanism. Id. at 819.
24. Id. at 810, 811. This provision has been labeled "a case of responsible paternalism." Pirt,
supra note 15, at 281.
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safe, and heat stable, would require a single dose for a lifetime, and would be
effective against all viral strains and all routes of exposure. 25 The vaccine could
be distributed and administered through a variety of channels using different legal
forms.26 Examples include direct sales by American pharmaceutical companies to
private or public clinics; sales through partially or wholly owned subsidiaries
located in the host or another foreign country, which could act either as conduits
or under licenses to manufacture and distribute American-engineered pharmaceu-
tical products; sales from foreign corporations that have licensing agreements
with U.S. corporations; or sales of vaccines under contracts between parent
or subsidiary corporations and foreign governments, the latter then organizing
distribution through state clinics or possibly, in rural areas, by village health
workers in traveling vans.
Before widespread administration, of course, clinical trials must first make sure
that a vaccine is both safe and efficacious. Such research will require thousands of
participants.27 Informed consent is critical in both the research and administration
phases. 2' Effective informed consent requires detailed warnings that describe
known contra-indications to administering entities and, if appropriate, direct re-
cipients. However, the consent process must conform to the cultural norms of
the participants.29 It is important to recognize that prevailing Western, and particu-
larly American, expectations, attitudes, and legal requirements will not necessar-
ily be the custom in other countries.
Many vaccine recipients in underdeveloped countries may be illiterate, render-
ing written communication for the purpose of consent meaningless. A large num-
ber of these recipients will be children.
In some cultures there is little perception of conflict between self and society, except
perhaps if the society is someone else's. For example, in the Indian subcontinent and
West Africa great deference may be given to clinicians/healers/elders. Decisions are
characteristically made in consultation with leaders in the setting of village meetings.
If permission has already been given by a community or family representative, the idea
of an informed refusal by the individual may not even arise. 
30
25. AIDS ACTION FOUNDATION, supra note 10, at 2.
26. See William Schurtman, Book Review, 23 Int'l Law. 774, 777 (1989) (reviewing WARREN
FREEDMAN, PRODUCT LIABILITY ACTIONS BY FOREIGN PLAINTIFFS IN THE UNITED STATES (1988)).
For an example of the intricate corporate arrangements that are possible to limit taxation or liability,
see infra notes 93-94 and accompanying text.
27. AIDS ACTION FOUNDATION, supra note 10, at i (Introduction).
28. Id. at 25; see International Covenant on Economic, Social and Cultural Rights, G.A. Res.
2200A (XXI), Dec. 16, 1966, 21 U.N. GAOR Supp. No. 16, at 49, U.N. Doc. A/6316 (1966),
993 U.N.T.S. 3, entered into force on Jan. 3, 1976, pt. III, art. 7, which states that "no one shall
be subjected without his free consent to medical or scientific experimentation."
29. Id. at 26; see also Joan E. Sieber, Ethical Considerations in Planning and Conducting
Research on Human Subjects, 68 ACAD. MED. S9-S13 (Sept. Supp. 1993).
30. Larry Gostin, Ethical Principles for the Conduct of Human Subject Research: Population-
Based Research and Ethics, 19 LAW, MED. & HEALTH CARE, RES. ON HUMAN POPULATIONS:
NATIONAL AND INTERNATIONAL ETHICAL GUIDELINES, Fall-Winter 1991, at 193 (citations omitted).
The author describes the process as "permission" and states that "researchers [still] have an ethical
obligation to seek consent from the individual." Id. at 194.
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In addition to the potential problems associated with obtaining informed con-
sent, other difficulties such as lack of telephones, money, and sophisticated labora-
tories, poor transportation, political upheaval, and in some impoverished parts
of the world, the disruptions caused by famine and war, will impede effective
immunization programs.3 Possibilities for accident and injury are clearly present.
Despite careful preliminary trials, there may be unanticipated reactions in the
form of increased vulnerability to HIV or harmful side effects.32 Production
problems are a possibility. For example, in 1976 two million swine flu doses
were made from the wrong virus.33 Additionally, contamination could occur in
the process of distribution, improper administration, or a failure to communicate
known hazards adequately. In this regard, the possibility always exists that protec-
tion could vary, causing some recipients to believe erroneously that infection is
no longer possible and that they can engage in risk-enhancing behavior.
4
II. Advantages of Bringing Suit Against a U.S. Manufacturer in the
United States and Defenses Against Such Suits
A. ADVANTAGES OF BRINGING SUIT IN THE UNITED STATES
A foreign plaintiff who has been injured by a vaccine might sue the local
medical personnel who dispensed the vaccine or attempted treatment thereafter,
the clinic where the vaccine was administered (unless it is state-operated and
sovereign immunity applies), or a local subsidiary corporation (of a U.S. manufac-
turer) that may have produced and marketed the vaccine. But in all likelihood,
particularly if vaccine-related injuries occurred on a wide, broadly reported scale,
the injured foreign plaintiff would attempt to bring suit in this country in state
or federal court against the U.S. pharmaceutical corporation that developed the
vaccine. An attempt might be made to hold a parent American company responsi-
ble for the acts of its foreign subsidiary.3 5 In the alternative, if research, develop-
31. Tina Susman, Zaire Doesn't Fit the Movie, S.F. CHRON., May 16, 1995, atA8. Even though
a vaccine for polio has been in existence for about four decades, only half of Africa's children have
been immunized. Id.
32. AIDS ACTION FOUNDATION, supra note 10, at 27; see also Robert L. Turner, Hurdles for
an AIDS Vaccine, BOSTON GLOBE, July 20, 1993, at 15.
33. Id.
34. AIDS ACTION FOUNDATION, supra note 10, at 8.
35. In the Bhopal litigation, the attempt within the United States was unsuccessful, but by returning
the case to India, the concept of responsibility was implicitly affirmed. In re Union Carbide Corp.
Gas Plant Disaster, 634 F. Supp. at 842; see also Obligations of a Company Belonging to an Interna-
tional Group and Their Effect on Other Companies of That Group, Institut de Droit International;
Session de Lisbonne, Fifteenth Commission, Draft Resolution Rev. 2, Aug. 29, 1995, H 2(b) ("Liabil-
ity for claims arising out of torts may be imputed to the controlling entity .. .in circumstances,
such as mass disasters, in which the resources of the member or members of the multinational
enterprise directly involved are insufficient to respond to the claim in full"), 11 2(c) ("Liability
... may also be imputed to another member of the multinational enterprise .. .when that other
member has participated in the activity on which the claim is based or has derived direct economic
benefit from that activity"), and II 3(a)(a)(i) and (ii) ("a parent company or a controlling entity of
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ment, and/or production took place in this country, a claim could be pressed that
the American company, itself, fell below an appropriate standard of care in its
research and testing, its manufacturing processes, or its warnings accompanying
product distribution.36 The legal theories, as in all actions arising from injury
caused by a product, would be breach of express or implied warranty, negligence,
or strict product liability in the form of production flaw, design defect or failure
to warn.37
Despite the apparent, enormous inconvenience, why would an injured foreign
plaintiff attempt to file a claim in the United States against the parent corporation?
The answer is twofold: the problematic nature of legal proceedings in many
countries, particularly those in the less developed world, and the attractive nature
of legal processes and doctrine in the United States. In a foreign country, the
plaintiff could encounter substantial delay, limited opportunities for discovery,
a lack ofjuries (and their potential pro-plaintiff biases) and contingent fee arrange-
ments, doctrine rooted in negligence rather than strict products liability, a poten-
tially nonindependent judiciary, and vastly limited damages relative to comparable
awards in the United States.38 Moreover, if a claim is filed in a foreign forum
against a U.S. corporation and a judgment is obtained, the plaintiff would, in
all likelihood, be compelled to enforce that judgment in the United States, because
the assets of the corporation would be located in the United States and not in
the foreign jurisdiction. 39 Thus, a second, costly legal proceeding would be re-
quired.4
a multinational enterprise is subject to .. .jurisdiction .. .on the basis .. .of the permanent
presence in the State of a branch or ... a subsidiary"); CASSELS, supra note 21, at 146-47 (in the
Union Carbide case, the argument of the Indian government was that a "parent company must, in
its dealings abroad, maintain responsibility for its subordinates").
36. See, e.g., Friends of All Children, Inc. v. Lockheed Aircraft Corp., 717 F.2d 602, 604
(D.C. Cir. 1983); Carlenstolpe v. Merck & Co., 638 F. Supp. 901, 903 (S.D.N.Y. 1986); Harrison
v. Wyeth Labs, 510 F. Supp. 1, 2-3 (E.D. Pa. 1980).
37. Almost all of these theories of liability were asserted in de Melo v. Lederle Labs, 801 F.2d
1058 (8th Cir. 1986).
38. In re Union Carbide Corp. Gas Plant Disaster, 634 F. Supp. at 847-51; see also Sheila
L. Birnbaum & Douglas W. Dunham, Foreign Plaintiffs and Forum Non Conveniens, 16 BROOK.
J. INT'L L. 241, 242 n.4 (citing Itzkowitz, Don't Denigrate the Indian Legal System, Nat'l L.J.,
Feb. 4, 1985, at 12).
39. GARY B. BORN & DAVID WESTIN, INTERNATIONAL CIVIL LITIGATION IN UNITED STATES
CouRTs 739-40 (2d ed. 1992).
40. The recognition of foreign judgments is governed by the laws of the states. Id. at 743,
770-72. Somportex, Ltd. v. Philadelphia Chewing Gum Corp., 318 F. Supp. 161, 164 (E.D. Pa.
1970); R. Doak Bishop & Susan Burnette, United States Practice Concerning the Recognition of
Foreign Judgments, 16 INT'L LAW 425 (1982). As a general proposition, U.S. courts are "far more
willing" to enforce Western European-and particularly English-judgments than judgments from
other nations. BORN & WESTIN, supra note 39, at 769. Nevertheless, assuming a foreign court has
properly asserted personal and subject matter jurisdiction, its judgment will be upheld even though
it applies a rule contrary to public policy in the United States. Id.; Somportex Ltd. v. Philadelphia
Chewing Gum Corp., 318 F. Supp. at 168-69. But enforcement will be denied if the judgment is
so unfair and so lacking in impartiality that it is outrageous, amounting to prejudice or fraud, or
if it runs "directly contrary to some fundamental policy of the forum." BORN & WESTIN, supra
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These restrictions substantially inhibit legal redress for injury, and for the poor
and ignorant the result can be no redress at all. But many of the difficulties
encountered in legal proceedings abroad evaporate if suit is brought directly in
the United States, and in consequence the American legal system operates like
a magnet attracting foreign claimants. 41 As an example, American lawyers were
on the scene within ten days of the gas plant explosion in Bhopal, India, and
145 class action suits were filed in U.S. federal district courts.42 Although in
that case the explosion most probably resulted from negligent plant maintenance, 3
a significant percentage of actions by foreign plaintiffs involves pharmaceuti-
cals." For a foreigner injured by a drug or vaccine developed in the United
States, there are multiple reasons why suit here would be attractive, and they
constitute virtual reciprocals of the reasons why suit is less attractive in foreign
jurisdictions: extensive discovery, contingent fees, jury trials, the availability of
strict products liability in most U.S. jurisdictions, greater expertise of American
attorneys in products litigation, better access to expert witnesses, the possibility
of punitive damages, pain and suffering as an element of damages, no liability
for the successful litigants' attorneys fees, and last, but by no means least, the
lure of relatively greater damage awards.45
The last-greater damage rewards-could constitute a windfall to a foreign
plaintiff far greater than a lifetime of earnings. Citizens of foreign countries who
are injured by U.S. technology or pharmaceuticals may earn a fraction of the
wages commanded by their counterparts in this country. By bringing suit in the
United States, they clearly hope to benefit from the largesse of a more lenient
legal system, although most U.S. courts would apply foreign law for an injury
incurred abroad, even on the damages question.46 If U.S. law is applied, however,
because the tortious conduct (for example, manufacturing or design defect) is
note 39, at 753; see id. at 753, 769 (citing Courtland H. Peterson, Foreign Country Judgments and
the Second Restatement of Conflict of Laws, 72 COLUM. L. REv. 220, 230-32 (1972)); CAL. CIV.
PROC. CODE § 1713.4(6)(3) (foreign judgment not recognized if cause of action or defense on which
judgment is based "is repugnant to the public policy of this state"); see also Ackermann v. Levine,
788 F.2d 830, 841, 844 (2d Cir. 1986). The doctrine of international comity, with its exceptions,
was articulated in Hilton v. Guyot, 159 U.S. 113, 202-03 (1885).
41. The United States has been described as "an El Dorado or promised land for foreign plain-
tiffs." Schurtman, supra note 26, at 776; see also Mary Sheinwold, International Products Liability
Law, 1 TouRo J. TRANSNAT'L L. 257, 260 (1988).
42. Birnbaum & Dunham, supra note 38, at 241.
43. The reasons and supporting evidence, however, were disputed. CASSELS, supra note 21, at
7-11.
44. Schurtman, supra note 26, at 776. Airplane crashes also constitute a significant percentage.
Id.
45. Id.; see also BORN & WESTIN, supra note 39, at 92-93, 222; Birnbaum & Dunham, supra
note 38, at 242; William L. Reynolds, The Proper Forum for a Suit: Transnational Forum Non
Conveniens and Countersuit Injunctions in the Federal Courts, 70 TEXAS L. REv. 1663, 1706-07
(1992); Sheinwold, supra note 41, at 257-58. Some of these factors are currently the target of reform
proposals.
46. RESTATEMENT (SECOND) OF CONFLICT OF LAWS §§ 145, 146, 156 et seq., 171 (1971).
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alleged to have taken place in this country, no rules govern the calculation of
damages. For example, should a damages verdict or settlement in this country that
takes into account the disparate earnings potential of U.S. and foreign plaintiffs be
discounted, contrary to the collateral source rule, for a state-run medical system
that may provide free medical care for all injuries sustained? Equal protection
for a nonresident alien would be based on only a rational basis review, and
discrimination against a foreign plaintiff under such a standard would be both
justifiable and plainly constitutional. 47 In the original settlement involving domes-
tic and foreign plaintiffs injured by silicone gel implants, the foreign claimants
complained of the considerable disparity in the amount allocated to each group
and a lack of standards or criteria for establishing these amounts. 48 The court
recognized that settlement values would be lower in other countries and took
account of the practical effect of factors such as jury trials, punitive and multiple
damages, and the extent of governmentally supported health care systems. 49 The
result seems to have been very much an educated guess, varying in size from
country to country. However, while a foreign claimant might receive a damages
award considerably below that which would be awarded a U.S. citizen, in many
cases the amount might still be enough to make filing a claim here a lucrative
proposition compared to the amount obtainable at home.
B. DEFENSE STRATEGIES TO AVOID SUIT IN THE UNITED STATES
1. Forum Non Conveniens
Forum non conveniens is a common law doctrine that allows a court to dismiss
a case brought by a foreign plaintiff, even though jurisdiction and venue are
47. Reynolds, supra note 45, at 1692.
48. Lindsay v. Dow Coming Corp., No. 94-P-i 1558-S, at 6,13 (N.D. Ala. 1994). Mike McKee,
Foreign Women Unhappy with "Global" Implant Settlement, THE RECORDER, Aug. 22, 1994,
at 1. The settlement unraveled after Dow Coming Corp. filed for bankruptcy. See Jay Matthews,
Breast Implant Maker Files for Bankruptcy, S.F. CHRON., May 16, 1995, at Al1; Withdrawal from
Implant Settlement Okd, S.F. CHRON., Oct. 10, 1995, at A2. A new Approval of Revised Settlement
Program and Injunctions, Order No. 27, filed December 22, 1995, provides compensation only for
domestic plaintiffs and eliminates foreign claimants, who may now file in their own courts or in
U.S. courts subject to dismissal for forum non conveniens. In the settlement of the Bhopal litigation
in India, individual amounts were "minuscule in comparison with amounts awarded for similar
injuries to persons in Western countries ... Awards to the families of deceased victims might
produce, after inflation, annual amounts of about $900 for twenty years ... Awards to those who
were permanently disabled might generate about $350 per year .... CASSELS, supra note 21, at
230. These awards did not guarantee future cost of income loss, subsistence, or medical care, nor
did it provide for pain and suffering. Id.
49. Lindsay v. Dow Coming Corp., No. CV94-P-11558-S, at 13 (N.D. Ala. 1994). Benefits
were established as a percentage of the amount for domestic plaintiffs on a country-by-country basis,
taking into account compensation typically awarded compensable injuries in those countries. Id. at
13-14. Any significant correlation between the breast implants and subsequent ills has been strongly
challenged by MARCIA ANGELL, THE CLASH OF MEDICAL EVIDENCE AND THE LAW IN THE BREAST
IMPLANT CASE (1996).
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proper, if the case should more appropriately be tried in a foreign forum.o Only
a defendant may invoke the doctrine." Within the federal system, change of
venue is effected by transferring the action to another district,52 whereas, when
a foreign plaintiff is involved, the result of a successful forum non conveniens
motion is outright dismissal,53 albeit dismissal frequently subject to limiting condi-
tions.m
The growth in international commercial activity and the increasing resort by
foreigners to redress in U.S. courts when they are injured abroad by American
products has sparked "an explosion of forum non conveniens litigation." 55 The
doctrine has won widespread acceptance.56 Most of the litigation is between
foreign plaintiffs and U.S. -based multinational corporations. 57 "The battle over
where the litigation occurs is typically the hardest fought and most important
issue in a transnational case; if the defendant wins this battle, the case is often
effectively over." 58 In consequence, from a defendant's standpoint, removing a
case from the United States is far more important than convincing a U.S. court
to apply foreign law.59
The forum non conveniens inquiry proceeds in four steps. First, the trial court
must ascertain whether an adequate alternative forum exists. Assuming a favor-
able response to the first inquiry, the court must next consider private interest
factors that bear on the litigation. If the private interest factors are in equipoise,
or near equipoise, the court must then consider public interest factors. Lastly,
if the balance tips toward the foreign forum, the court can dismiss for forum
50. Jacqueline Duval-Major, Note, One-Way Ticket Home: The Federal Doctrine of Forum Non
Conveniens and the International Plaintiff, 77 CORNELL L. REv. 650 (1992).
51. Id.
52. 28 U.S.C. § 1404(a) (1990).
53. Duval-Major, supra note 50, at 652, 656.
54. Allin C. Seward III, After Bhopal: Implications for Parent Company Liability, 21 INT'L
LAW. 695, 697, 702-04 (1987). Typical limiting conditions are defendant's consent to suit in the
foreign jurisdiction, acceptance of jurisdiction by the foreign court, defendant's waiver of the statute
of limitations after filing in the U.S. court, and defendant's amenability to discovery. Ledingham
v. Parke-Davis Div. of Warner Lambert Co., 628 F. Supp. 1447, 1452-53 (E.D.N.Y. 1986); see
also In re Union Carbide Corp. Gas Plant Disaster, 634 F. Supp. at 867.
55. Reynolds, supra note 45, at 1665. Many of the plaintiffs are solicited abroad by American
lawyers. Id. at 1671.
56. Id. at 1664-65.
57. Duval-Major, supra note 50, at 670.
58. David W. Robertson & Paula K. Speck, Access to State Courts in Transnational Personal
Injury Cases: Forum Non Conveniens and Antisuit Injunctions, 68 TEXAS L. REv. 937, 938 (1990)
(footnotes omitted). "[O]nly an outright dismissal with prejudice could be more 'outcome-
determinative' than a [forum non conveniens] dismissal to a distant forum in a foreign land." Id.
n.4 (citing In re Air Crash Disaster, 821 F.2d 1147, 1156 (5th Cir. 1987)) (en banc), vacated sub
nom. Pan Am. World Airways, Inc. v. Lopez, 490 U.S. 1032, aff'd in part and vacated in part,
883 F.2d 17 (5th Cir. 1989).
59. Robertson & Speck, supra note 58, at 942.
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non conveniens, but only if the plaintiff can reinstate suit without substantial
inconvenience or prejudice. 60
In its original formulation, the plaintiffs choice of forum could rarely be
disturbed absent oppressiveness and vexation to a defendant out of all proportion
to a plaintiff's convenience or considerations affecting the court's own administra-
tive and legal problems.61 However, in Piper Aircraft Co. v. Reyno,62 the Supreme
Court concluded that the presumption in favor of the plaintiffs choice of forum
deserves less deference when the plaintiff is foreign.63 The Piper Court was
concerned that U.S. multinationals would become the target of tort litigants from
around the world. 64 It also wanted to help U.S. courts "avoid conducting complex
exercises in comparative law," 65 and, indeed, forum non conveniens decisions
are often choice of law decisions in disguise,66 although convenience and choice
of law are analytically distinct. However, the shift to less deference-and away
from weighing private and public interest factors in favor of the plaintiff-has
meant in practice little or no deference when the plaintiff is neither a U.S. citizen
nor a resident. 67 From that plaintiffs point of view, the doors of the federal
courts are virtually closed when they bring product liability suits against U.S.
corporations for injuries suffered abroad. 68 The consequence is an increasing
60. Friends of All Children, 717 F.2d at 606; see also Frazier v. St. Jude Medical, Inc., 609
F. Supp. 1129, 1130-31 (D. Minn. 1985). The private interest factors include ease of access to
sources of proof, availability of compulsory process for attendance of unwilling witnesses, the cost
of obtaining attendance of willing witnesses, the possibility of a view of the premises, and the
enforceability of the judgment. Gulf Oil Corp. v. Gilbert, 330 U.S. 501, 508 (1947). Factors of
public interest include the administrative difficulties that arise when litigation piles up in congested
centers, the burden of jury duty, and the local interest in having localized controversies decided at
home. Id. at 508-09. The convenience of the parties is rarely a factor; rather, the principal issues
involve the location of evidence, costs, adequate discovery, local practices, and the ability to implead
third parties. Reynolds, supra note 45, at 1672-77.
61. Koster v. Lumbermens Mutual Casualty Co., 330 U.S. 518, 524 (1947); Gulf Oil v. Gilbert,
330 U.S. at 508.
62. 454 U.S. 235 (1981).
63. Id. at 255. Moreover, the Court concluded that the possibility of a change in substantive
law should ordinarily not be given conclusive or even substantial weight in the forum non conveniens
inquiry. Id. at 247, 254; see also Duval-Major, supra note 50, at 647. However, under Friendship,
Commerce, and Navigation treaties, which give foreign citizens the same access to U.S. courts as
nonresident U.S. citizens, the Piper standard of less deference does not apply. Id. at 658 (citing
Allen J. Stevenson, Forum Non Conveniens and Equal Access Under Friendship, Commerce and
Navigation Treaties: A Foreign Plaintiff's Rights, 13 HASTINGS INT'L & COMP. L. REv. 267, 277-78
(1990)); see also Reynolds, supra note 45, at 1692.
64. BoRN & WESTIN, supra note 39, at 303.
65. Piper Aircraft Co. v. Reyno, 454 U.S. at 251; see also de Melo v. Lederle Labs, 801 F.2d
1058, 1064 (8th Cir. 1986).
66. Laurel E. Miller, Comment, Forum Non Conveniens and State Control of Foreign Plaintiff
Access to U.S. Courts in International Tort Actions, 58 U. CHI. L. Rav. 1369, 1391 (1991).
67. Id. at 1369; Piper Aircraft Co. v. Reyno, 454 U.S. at 242, 255; Duval-Major, supra
note 50, at 657-58.
68. Miller, supra note 66, at 1369; Robertson & Speck, supra note 58, at 940.
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resort to state courts, 69 but even there the doctrine of forum non conveniens
generally follows the federal standard.7 °
If no adequate alternative forum exists;71 if a foreign forum is manifestly biased,
unfair, or unequipped for a particular case;72 or if virtually no remedy whatsoever
is available, 73 a motion for forum non conveniens dismissal will be denied. But
the fact is that "courts have found the foreign forum inadequate only in extreme
cases." 74 Dismissal effectively ends the case, leaving most foreign plaintiffs with
little or no recourse at home.75 Moreover, once the trial court has ruled on the
motion, the decision is given substantial deference on appeal.76
Dismissal for forum non conveniens has been granted when the treating doctor
and distributing corporation are in the foreign country; 77 where a drug is manufac-
tured, packaged, advertised, promoted, and marketed by a separate and indepen-
dent foreign subsidiary; 78 and where a product license is issued under the laws
of a foreign country.79 In the case of Harrison v. Wyeth Laboratories,° even
though the fundamental manufacturing and marketing decisions and the withhold-
ing of an adequate warning were alleged to have taken place in the United States,
69. Id.
70. Duval-Major, supra note 50, at 659. A detailed breakdown of the approaches followed in
the states may be found in Robertson & Speck, supra note 58, at 950 & nn.73-80. An example of
a state court decision that follows Piper Aircraft and Gilbert is Stangvik v. Shiley, 819 P.2d 14 (Cal.
1991), although the California Supreme Court noted that "the cumulative connection of the defendant
and its conduct within the state is relevant." Id. at 24. It is still "an open question as to whether
federal courts sitting in diversity must apply federal or state law" to a forum non conveniens motion.
Birnbaum & Dunham, supra note 38, at 249 (citing Piper Aircraft Co. v. Reyno, 454 U.S. 235,
248 n.13 (1981); Sibaja v. Dow Chem. Co., 757 F.2d 1215, 1219 (1lth Cir.), cert. denied, 474
U.S. 948 (1985)); Stein, Forum Non Conveniens and the Redundancy of Court-Access Doctrine,
133 U. PA. L. REv. 781, 820 (1985)).
71. BORN & WESTIN, supra note 39, at 312.
72. Id. at 314.
73. See Irish Nat'l Ins. Co. v. Aer Lingus Teoranta, 739 F.2d 90 (2d Cir. 1984); see also BORN
& WESTIN, supra note 39, at 286-87.
74. Reynolds, supra note 45, at 1668.
75. Id. at 1689 (citing David W. Robertson, Forum Non Conveniens in America and England:
"A Rather Fantastic Fiction," 103 LAW Q. REv. 398, 419 (1987) (reporting a survey showing that
only 3 of 85 cases dismissed by U.S. courts on forum non conveniens grounds resulted in judgment
in a foreign court, and 10 more cases were pending)). These figures, however, are consistent with
the percentage of tort cases that are tried in the United States. Justice Department Study Finds 75
Percent of Tort Cases Settle, Three Percent Go to Trial, 2 CIv. JUST. DIG., Summer 1995, at 5;
Duval-Major, supra note 50, at 651, 672; Miller, supra note 66, at 1388.
76. Piper Aircraft v. Reyno, 454 U.S. 235, 257 (1981); Hodson v. A.H. Robins Co., 715 F.2d
142, 144 (4th Cir. 1983); de Melo v. Lederle Labs, 801 F.2d 1058, 1061 (8th Cir. 1996); Carlenstolpe
v. Merck & Co., 638 F. Supp. 901, 904 (S.D.N.Y 1986); see also Reynolds, supra note 45, at
1686, who points out that, because appellate courts must engage in meaningful review, they tend
to ignore the standard and engage in de novo review.
77. de Melo v. Lederle Labs, 801 F.2d 1058, at 1063.
78. Ledingham v. Parke-Davis Div. of Warner-Lambert Co., 628 F. Supp. 1447, 1449
(E.D.N.Y. 1986).
79. Harrison v. Wyeth Laboratories, 510 F. Supp. 1 (E.D. Pa. 1980), aff'd, 676 F.2d 685 (3d
Cir. 1982); McCracken v. Eli Lilly & Co., 494 N.E.2d 1289, 1291 (Ind. Ct. App. 1986).
80. Harrison v. Wyeth Laboratories, 510 F. Supp. at 1.
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the court was sensitive to the legitimate concerns and unique needs of the foreign
country.8' In granting the forum non conveniens motion, the court noted that the
U.S. parent corporation should not be immunized from liability, but the court
also believed that it should not impose American notions of safety and risk on
a foreign country that might have a "vastly different standard of living, wealth,
resources, level of health care and services, values, morals and beliefs than
our own.' ' These concerns are only exacerbated when evidence of preexisting
medical conditions, the knowledge of treating physicians, and the nature and
extent of adverse reactions-in short, evidence of causation, liability, and dam-
ages-are located in the foreign country.83
Other courts have gone the other way. In terms of injury caused by a drug or
vaccine, much appears to depend on how expansively or narrowly courts construe
the interest of the United States in regulating and controlling its manufacturers'
conduct overseas. a4 As one commentator has noted:
Recent products liability cases involving prescription drugs suggest that whether the
balance tips in favor of the plaintiff's choice or in favor of a foreign forum depends
upon (1) the extent of the American manufacturer's active participation in the design,
development, testing, labelling and marketing of the allegedly defective product; and
(2) the court's view of whether the chosen forum's interest in product safety and in
regulating manufacturer conduct within its borders properly extends to transactions and
events occurring beyond its borders.85
When the litigation involves behavior that occurs in the United States-for exam-
ple, when a drug is developed, tested, and manufactured in this country; approved
by the FDA; and used by American citizens-then American courts have refused
to dismiss the action. 86 The courts distinguish cases that involve products developed
in the United States but manufactured overseas. 87 Courts have also considered the
burden of obtaining translations, different discovery rules, and the lack of contin-
gent fees. 88 Of perhaps greater import, ease of access to sources of proof in the
United States, including witnesses, has helped determine the outcome. 89 In addi-
tion, although not an articulated factor, it is arguable that the revolution in transpor-
81. Id. at 3-4, 8.
82. Id. at 4.
83. Birnbaum & Dunham, supra note 38, at 255. Dismissal is likely if no plaintiff is an American
citizen, no significant events occurred in the United States, and foreign law controls. Reynolds,
supra note 45, at 1681.
84. Sheila L. Birnbaum & Barbara Wrubel, Foreign Plaintiffs and the American Manufacturer:
Is a Court in the United States a Forum Non Conveniens? 20 FORUM 59, 67 (1984).
85. Id. at 65.
86. Carlenstolpe v. Merck & Co., 638 F. Supp. 901,906-09 (S.D.N.Y. 1986); Hodson v. A.H.
Robins Co., 715 F.2d 142, 143 (4th Cir. 1983); Birnbaum & Dunham, supra note 38, at 252.
87. Carlenstolpe v. Merck & Co., 638 F. Supp. at 908. Arguably, if the crux of the plaintiff's
complaint is defect in design, the foreign place of manufacture should not make a difference.
88. Joaquim Macedo v. Boeing Co., 693 F.2d 683, 688 (7th Cir. 1982).
89. Irish Nat'l Ins. Co. v. Aer Lingus Teoranta, 739 F.2d 90, 92 (2d Cir. 1984); Friends of
All Children, Inc. v. Lockheed Aircraft Corp., 717 F.2d 602, 608-09 (D.C. Cir. 1983).
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tation and communication and the deliberate dispersion of corporate authority
through the creation of multinational subsidiaries call for a reexamination of the
lesser deference given to a foreign plaintiff's choice of forum. 90
2. Corporate Form
A corporation may avoid potential liability through the creation of an organiza-
tional structure that locates responsibility for tortious behavior in legally separate
corporate entities. 9' Company law tends to focus on each individual entity, grant-
ing to each limited liability and not piercing the corporate veil. 92 The general
rule, therefore, is that an American corporation that establishes an independent
foreign subsidiary to manufacture and/or sell a product later found to be defective
is not individually liable as a parent corporation.93
The labyrinthine, multilayered corporate structures that result are a testament to
human-and particularly lawyerly-ingenuity. As an example, albeit in a different
context, take the case of De Mateos v. Texaco, Inc. ,94 which involved a suit,
dismissed on forum non conveniens grounds, brought by a mother for the death
of her son, a seaman aboard a ship of Liberian registry owned by Texpan, a
Panamanian corporation. Texaco Overseas Tankship Limited (TOT), a United
Kingdom corporation with its principal place of business in London, managed
the ship. TOT was a wholly owned subsidiary of Texaco Limited, another United
Kingdom corporation with its principal place of business in London. Texaco
Limited was wholly owned by Texas Operations (Europe) Ltd. (TOEL), a Dela-
ware corporation. Texaco Inc. (the defendant), also a Delaware corporation,
owned all the stock of TOEL and of Texpan.95
Many forum non conveniens cases involve attempts to penetrate these complex
corporate mazes, leapfrogging a local subsidiary in order to bring suit directly
against the American corporate parent. 96 When the subsidiary is wholly owned,
rather than the creature of a joint venture, and is part of a complex multinational
90. See Fitzgerald v. Texaco, Inc., 521 F.2d 448, 456 (2d Cir. 1975) (Oakes, J., dissenting),
cert. denied, 423 U.S. 1052 (1976).
91. Enterprises linked by ownership that share knowledge, resources, and responsibilities include
incorporated branches, subsidiaries, and joint ventures. Watter Kolvenbach, European Reflections
on Bhopal and the Consequences for Transnational Corporations, INT. Bus. LAW., Nov. 1986,
at 358.
92. Id. at 359.
93. Affiliated v. Trane Co., 831 F.2d 153, 155 (7th Cir. 1987). Bewers v. American Home
Prods. Corp., 474 N.E.2d 247 (N.Y. 1984). But see Obligations of a Company Belonging to an
International Group, supra note 35.
94. 562 F.2d 895 (3d Cir. 1977).
95. Id. at 897-98. For other examples, see Fitzgerald v. Texaco, Inc., 521 F.2d 448, 455 (2d
Cir. 1975); McCracken v. Eli Lilly & Co., 494 N.E.2d 1289, 1291 (Ind. Ct. App. 1986); see also
Robertson & Speck, supra note 58, at 939 nn.13, 14.
96. Dowling v. Richardson-Merrell, Inc., 727 F.2d 608, 610-11 (6th Cir. 1984); Harrison v.
Wyeth Laboratories, 510 F. Supp. 1, 3 (E.D. Pa. 1980); see also de Melo v. Lederle Labs, 801
F.2d 1058, 1059 (8th Cir. 1986).
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enterprise that is ultimately directed and controlled in the United States, the
temptation to bring suit in the United States is particularly strong despite dispersed
decision making, separate boards of directors, and overseas manufacturing and
research facilities . The fact that U.S. courts grant forum non conveniens motions
against parent companies subject to conditions indicates a willingness to look
behind the corporate form and find a kind of multinational enterprise liability. 9'
Implicit is an acknowledgment of a central decision-making structure, without
regard for legal personality, and a recognition that modem management forms
have rendered older forms at least partially obsolete. 9
As a practical matter, this point of view may make sense. In the sale of pharma-
ceuticals, the general trend is toward collaboration between American and foreign
companies, and an ever-increasing percentage of American drug production is
performed by foreign-based subsidiaries of U.S. parent firms.'0° Nevertheless,
permitting suit against an American firm for injuries resulting from a vaccine
manufactured overseas by its foreign subsidiary could dampen distribution efforts
and represents "a variety of social jingoism, which presumes that the 'liberal
purposes' of American law must be exported to wherever our multinational corpo-
rations are permitted to do business."l 0 '
3. Contractual Provisions
If a vaccine is administered privately, as it could and would be in many coun-
tries, the company responsible for its manufacture and distribution might attempt
to obtain a release from liability as part of the consent to treatment. However,
in addition to the fact that many recipients would fail to understand the full nature
of such a provision,' °2 an attempt to avoid a general tort obligation through
contract would presumably fail on public policy grounds. Conditioning an essen-
tial service-and surely an AIDS vaccine would fit into that category-on the
waiver of any legal redress could not constitute a legally enforceable, express
assumption of risk.'03
Most vaccinees, however, would probably receive the vaccine through part
of a massive government effort, and distribution would take place in public clinics
or at the hands of local public health officials. Thus, a drug company would sell
the vaccine to the foreign government, or to an agency or instrumentality of the
government, and not to individual recipients. The government would then clearly
97. Kolvenbach, supra note 91, at 359.
98. Seward, supra note 54, at 704; Kolvenbach, supra note 91, at 359; In re Union Carbide
Corp. Gas Plant Disaster, 634 F. Supp. at 867; Ledingham v. Parke-Davis Div. of Warner Lambert
Co., 1628 F. Supp. 1447, 1452-53 (1986).
99. Kolvenbach, supra note 91, at 357, 360.
100. Pirt, supra note 15, at 266-67.
101. De Mateos v. Texaco, Inc., 562 F.2d 895, 902 (3d Cir. 1977).
102. See supra notes 29-30 and accompanying text.
103. See, e.g., TunkI v. Regents of Univ. of Cal., 383 P.2d 441 (Cal. 1963).
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be part of the chain of distribution. Nevertheless, if the vaccine were defective
or administered negligently, the government might escape liability in its own
courts through either sovereign immunity, the absence in its law of a doctrine
of strict products liability, or the absence of a rule, as in the United States, that
imposes liability on a conduit in the chain of distribution. 104 If, instead, the foreign
government were made a party to a suit in the United States, it would probably
escape liability by invoking the Foreign Sovereign Immunity Act or the "act of
state" doctrine. 10 5 And, no doubt, it would move for dismissal on the basis of
forum non conveniens.
In the most likely scenario, however, the foreign government would not be a
defendant. Rather, it would function as plaintiff acting as representative of its
injured citizens.'°6 This last is what happened with regard to the Indian citizens
injured by the gas plant explosion at Bhopal, even though government regulatory
failures were strongly indicated as partly responsible for the disaster.l°7
In its contract for the sale of the vaccine to the foreign government, an American
pharmaceutical corporation could bargain for choice of law and choice of forum
clauses. 108 In the event of a dispute between the parties, these clauses could compel
104. W. PAGE KEATON ET AL., PROSSER AND KEATON ON THE LAW OF TORTS § 100(4) (5th ed.
1984).
105. The Foreign Sovereign Immunity Act, 28 U.S.C.A. §§ 1300, 1602-1611, grants a foreign
state immunity from jurisdiction in U.S. courts unless one of several statutorily defined exceptions
applies. Republic of Argentina v. Weltover, Inc., 504 U.S. 607, 610-11 (1992). One exception is
for commercial activity giving rise to a tort outside the United States that causes a direct effect in
the United States. 28 U.S.C.A. § 1605(a)(2). But, arguably, distribution of an AIDS vaccine would
not be such an activity if, after purchase, the vaccine were administered without charge or at least
without profit. Moreover, there would appear to be no direct effect in the United States. Sudano v.
Federal Airports Corp., 699 F. Supp. 824, 826 (D. Haw. 1988) (direct effect must be substantial
(citing Zernicek v. Brown & Root, Inc., 826 F.2d 415, 417 (5th Cir. 1985), cert. denied, 484 U.S.
1043 (1988)); Tucker v. Whitaker Travel Ltd., 620 F. Supp. 578 (D. Pa. 1985), aff'd, 800 F.2d
1140, cert. denied, 479 U.S. 986 (1986). There is also no sovereign immunity when a foreign state
waives its immunity either explicitly or by implication. 28 U.S.C.A. § 1605(a)(1). The "act of
state" doctrine precludes American courts from inquiring into the validity (or legality) of the public
acts committed by a recognized foreign state within its own territory. Arango v. Guzman Travel
Advisors Corp., 621 F.2d 1371, 1380 (5th Cir. 1980); Eckert Int'l v. Government of Fiji, 834 F.
Supp. 167, 171 (D. Va. 1993). Presumably, distribution of an AIDS vaccine by a foreign government
to its own citizens would be a public, not a commercial, act.
106. See, e.g., In re Union Carbide Corp. Gas Plant Disaster, 634 F. Supp. at 844; CASSELS,
supra note 21, at 118-19.
107. CASSELS, supra note 21, at 16, 22-25, 120.
108. BORN & WESTIN, supra note 39, at 223. Forum selection clauses, if the result of a freely
negotiated, private international commercial agreement, are enforceable unless they are unreasonable
(due to serious inconvenience), unjust, or invalid because of fraud or overreaching. The Bremen v.
Zapata Off-Shore Co., 407 U.S. 1, 9, 16 (1972); Carnival Cruise Lines, Inc. v. Shute, 499 U.S.
585, 595 (1991). "Only rarely (and usually not explicitly)" have U.S. courts "relied on the alleged
bias of a foreign forum to deny enforcement to a forum selection clause." BORN & WESTIN, supra
note 39, at 263 (citing cases). Forum selection clauses will usually be enforced by U.S. courts even
when the choice is the foreign party's home country. Id. at 273-74. Similarly, most U.S. courts
enforce choice of law provisions unless they violate an important public policy of the forum state,
or the choice of law lacks a reasonable relation to the parties' transaction, because it appears to
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litigation in a country with more favorable substantive law and procedural rules
than could be found in the United States.'t09 The advantages of forum non conveniens
could, in effect, be written into the contract." 0 However, it is not clear that injured
individuals, even individuals represented by their government, would be bound by
their government's contract clauses. If redress in their home courts would be very
difficult or impossible to obtain, a forum in the United States might still be available,
as discussed more fully in the next section of this article.
m. Should Suit in the United States against a U.S. Pharmaceutical
Corporation Be Permitted?
A. ARGUMENTS IN FAVOR OF SUIT IN THE UNITED STATES
The parochial advantages to a foreign claimant of bringing suit in the United
States were set forth in the preceding section."' The concerns of such a plaintiff
are rooted largely in questions of legal procedure, doctrine, and assessment of dam-
ages, and defenses such as forum non conveniens seem similarly rooted in the prac-
tical details of access to proof, docket congestion, and choice of law." 2 Tran-
scending these matters is an issue of more general concern: Does it make sense
from a policy perspective for a United States corporation, in particular a large,
multinational corporation, to shield itself from liability in a world that is increas-
ingly interconnected due to advances in transportation and communication technol-
ogy? Specifically, to address the theme of this article, does it make sense for a U.S.
pharmaceutical company that has developed an AIDS vaccine for desperate recipi-
ents throughout the world to avoid all responsibility if the vaccine causes injuries?
There are cogent reasons for permitting liability. Since 1947, when the Supreme
Court first adopted the doctrine of forum non conveniens, major changes have oc-
circumvent local laws when a local transaction is involved. Id. at 229-30. The corporation might
also attempt to secure a full indemnity provision, but, depending on the urgency of the need, it is
unlikely that most, if any, governments would agree to it.
109. "Because judicial systems, procedural rules, substantive law, choice-of-law principles and
political climates vary significantly from country to country, the selection of the forum can often
have an important influence on the outcome of the litigation." BORN & WESTIN, supra note 39, at
22. Factors bearing on forum selection, e.g., discovery, awarding costs, size of damage awards,
and exchange controls, are set forth in detail. Id.
110. However, if factors are present such as unequal bargaining power or inconvenience, a U.S.
court could ignore a forum selection clause and, under a reasonableness analysis, entertain the action.
RESTATEMENT (SECOND) OF CONFUCT OF LAWS § 80 cmt. c (1986). Colonial Leasing Co. v. Pugh
Brothers Garage, 735 F.2d 380, 382 (9th Cir. 1984). Although agreement in advance on a forum
acceptable to both parties is an indispensable element in international trade, The Bremen v. Zapata
Off-Shore Co., 407 U.S. at 13-14, the choice of forum should be unenforceable if it contravenes a
strong public policy of the forum where suit is brought or where enforcement would be unreasonable
and unjust due to fraud and overreaching. Id. at 15. Moreover, "the tort law of a foreign country
will not be applied if that country is shown to be 'uncivilized.' " Zschernig v. Miller, 389 U.S.
429, 461-62 (1968) (Harlan, J., concurring), a term of imprecise and possibly outdated meaning.
111. See supra notes 38-45 and accompanying text.
112. See supra notes 60-76 and accompanying test.
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curred in the worldwide organizational scope of business operations and in the link-
age of different parts of the globe through advances in the speed and efficiency of
transportation and communication. 13 Large multinational corporations command
the resources to take advantage of these advances, 114 which have substantially amel-
iorated the difficulties associated with obtaining witnesses and transporting docu-
ments. 115 It makes sense to permit suit in the United States under U.S. law when,
in addition to research and development, a U.S. corporation engages directly in
the manufacture of a product and its subsequent distribution from these shores.
Under such circumstances, a state would have a significant interest in regulating
the quality of production within its borders, as crucial evidence would be located
at the site of manufacture as well as at the site of injury."l6
Even if manufacturing takes place overseas by a foreign subsidiary, the degree
of control exercised by the American parent over the foreign operation should be
a crucial consideration. Limited responsibility cannot be defended when a local
entity does not have power to make its own decisions." 7 If the parent's role is re-
stricted to overall strategy and establishing general policies, and if the subsidiary
has substantial autonomy in operational matters, the argument is much stronger that
the parent should be immune from liability. "' But even when autonomy is granted, a
parent should be responsible for insuring quality control. " 9 It seems indefensible
to argue that a parent U.S. corporation, responsible for research and development,
could thereafter delegate responsibility for both a decision whether or not to warn
of possible, known adverse consequences and the contents of the warning.' 20
The most troubling issue involves the important, but ephemeral, question of
national policy and image. Opponents of the notion that foreign nations adequately
113. Duval-Major, supra note 50, at 651. -[Tlhe assessment of whether the balance of public
and private interests strongly overcomes the plaintiff's choice of forum must be made in light of the
realities of modern transportation and communications.... Jet travel and satellite communications
have significantly altered the meaning of 'non conveniens.' "Calavo Growers v. Generali Belgium,
632 F.2d 963, 969 (2d Cir. 1980) (Newman, J., concurring); see also Overseas Nat'l Airways v.
Cargolux Airlines Int'l, 712 F.2d 11, 14 (2d Cir. 1983) (Oakes, J., concurring).
114. Duval-Major, supra note 50, at 677.
115. Birnbaum & Dunham, supra note 38, at 256 (citing Manu Int'l, S.A. v. Avon Prods. Inc.,
641 F.2d 62, 65 (2d Cir. 1981) (quoting Fitzgerald v. Texaco, Inc., 521 F.2d 448, 456 (2d Cir.
1975) (Oakes, J., dissenting)); Note, Foreign Plaintiffs and Forum Non Conveniens: Going Beyond
Reyno, 64 Tax. L. REv. 193, 216 (1985)).
116. Carlenstolpe v. Merck & Co., 638 F. Supp. 901, 909-10 (citing In re Air Crash Disaster,
769 F.2d 115 (3d Cir. 1985)); see also Birnbaum & Dunham, supra note 38, at 258. For a discussion
of interest analysis in resolving a conflicts of law question, see RUSSELL J. WEINTRAUB, COMMENTARY
ON THE CONFLICT OF LAWS 315-23 (3d ed. 1986); Hertado v. Superior Court, 11 Cal. 3d 574 (1974).
117. Kolvenbach, supra note 91, at 359. It would matter, too, whether the foreign subsidiary
was wholly owned.
118. Seward, supra note 54, at 706-07.
119. Id. at 707; Kolvenbach, supra note 91, at 361.
120. See de Melo v. Lederle Labs, 801 F.2d 1058, 1065 (8th Cir. 1986) (Swygert, J., dissenting).
A multinational corporation that has chosen to do business abroad should not, by that fact, evade
U.S. law, particularly as the decision to warn was made in the United States by an American employee.
Id.; see also Obligations of a Company Belonging to an International Group, supra note 35.
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protect their citizens from corporate predators argue that multinational corpora-
tions search for countries that offer the lowest cost and highest return, and part
of the low cost may be attributed to low regulatory standards and less sophisticated
tort systems than in the United States..21 "The largest United States-based [multi-
national corporations] earn an average of forty percent of their net profits outside
the United States."'' 2 Should this country, through the rules governing forum
non conveniens dismissals, appear to condone the reaping of these profits in
countries where injured plaintiffs have little chance of vindication?'23 Should the
deterrent effect of tort liability be based upon whether harm takes place at home
or overseas? Variable rules make it appear that the United States itself is engaged
in harmful conduct or, at the least, is indifferent to its consequences if gross
national product is increased at the expense of foreign nationals.24 To avoid this
perception, imposing regulatory standards on U.S. multinational corporations
should be within the legitimate scope of U.S. foreign policy and would avoid
the appearance of a double standard that damages the U.S. image abroad.'25
B. ARGUMENTS OPPOSED TO SUIT IN THE UNITED STATES
Despite the aforementioned arguments, American corporations with foreign
subsidiaries need not fear the imminent demise of the forum non conveniens
doctrine.126 Most U.S. courts have concluded that they do not have a significant
interest in regulating the sale of products outside the United States.127 When a
drug is manufactured and marketed in a foreign country under a license granted
by that country, and where the injury takes place in that country, U.S. courts
are loathe to entertain jurisdiction even though development and testing took
place in the United States. 2 8
121. Duval-Major, supra note 50, at 674-75.
122. Id. at 675. But 80% of profits overseas from the sale of pharmaceuticals are derived from
the developed, not the developing, world. Pirt, supra note 15, at 271.
123. Duval-Major, supra note 50, at 673; see also de Melo v. Lederle Labs, 801 F.2d at 1065
(Swygert, J., dissenting), where plaintiff's witness testified that the case could take twenty years to
be heard and that plaintiff might not recover even $10,000, despite permanent blindness caused by
defendant's drug.
124. Duval-Major, supra note 50, at 675.
125. Miller, supra note 66, at 1386 (citing Note, Exporting Hazardous Industries: Should American
Standards Apply? 20 N.Y.U. J. INT'L &PoL. 777, 782-83 (1988); Note, An Economic Approach
to Forum Non Conveniens Dismissals Requested by U.S. Multinational Corporations, 22 GEo. WASH.
J. INT'L & EcoN. 215 (1988)).
126. Seward, supra note 54, at 705.
127. Birnbaum & Dunham, supra note 38, at 259; Reynolds, supra note 45, at 1695 (citing David
W. Robertson, Forum Non Conveniens in America and England: "A Rather Fantastic Fiction," 103
LAW Q. REv. 398, 405 (1987)).
128. Dowling v. Richardson-Merrell, Inc., 727 F.2d 608, 615-16 (6th Cir. 1984); Reynolds,
supra note 45, at 1681 (arguing that "[tihe country where the injury occurred has a greater interest
in the ensuing products liability litigation than the country where the product was manufactured")
(citing Kryvicky v. Scandinavian Airlines Sys., 807 F.2d 514, 517 (6th Cir. 1986)); see also Overseas
Nat'l Airways v. Cargolux Airlines Int'l, 712 F.2d 11, 12 (2d Cir. 1983).
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Indeed, imposing U.S. law with respect to safety, warnings, and duty of care
in the resolution of a problem that arises in a foreign country might be viewed
as a form of unwarranted paternalism. This would be particularly so if the foreign
government conducted the activity or had enacted a comprehensive regulatory
scheme to control the activity in question. 129 Even when production and marketing
decisions are made in the United States, one court has stated that:
Faced with different needs, problems and resources [a foreign country] may, in balancing
the pros and cons of a drug's use, give different weight to various factors than would
our society, and more easily conclude that any risks associated with the use of a particular
[drug] are far outweighed by its overall benefits to [the country] and its people. Should
we impose our standards upon them in spite of such differences? We think not." 0
... [I]t is manifestly unfair to the defendant, as well as an inappropriate usurpation
of a foreign court's proper authority to decide a matter of local interest, for a court
in this country to set a higher standard of care than is required by the government of
the country in which the product is sold and used.'
3 l
The incremental deterrence gained by bringing suit in the United States would
have, according to Justice Marshall, only an "insignificant" impact. 132 And suing
a corporate parent in the United States would breach notions of separate corporate
personality and limited liability that are widely relied upon to encourage economic
development and foreign investment. 1
33
Moreover, as mentioned previously,' 34 permitting foreign claimants to sue in
this country under U.S. law could result in vastly inflated recoveries relative to
what they might receive at home. This risk, in the final analysis, may be the
most significant reason to limit suits by foreigners against U.S. corporations.
The threat. of substantial liability raises costs for American firms competing
129. Seward, supra note 54, at 706; Miller, supra note 66, at 1384. One author has suggested
a "low road" approach in which a recipient country is warned of danger; the persons at risk may
never be informed, but the foreign government would decide how to confront the danger, and a
paternalistic approach would be avoided. Thomas 0. McGarity, Bhopal and the Export of Hazardous
Technologies, 20 TEx. INT'L L.J. 333, 335 (1985). Moreover, under the act of state doctrine in its
traditional formulation, the courts of this country may not inquire into the validity of the public acts
of a foreign sovereign power within its own territory. Banco Nacional de Cuba v. Sabbatino, 376
U.S. 398, 401,439 (1964). The most recent clarification of the act of state doctrine is W.S. Kirkpatrick
& Co. v. Environmental Textonics Corp., Int'l, 493 U.S. 400 (1990).
130. Harrison v. Wyeth Laboratories, 510 F. Supp. 1, 4-5 (E.D. Pa. 1980), aff'd, 676 F.2d 685
(3d Cir. 1982); see also McCracken v. Eli Lilly & Co., 494 N.E.2d 1289, 1293 (Ind. Ct. App.
1986); In re Union Carbide Corp. Gas Plant Disaster, 809 F.2d at 201; see also Weintraub, supra
note 116, at 353.
131. Harrison v. Wyeth Laboratories, 510 F. Supp. at 5.
132. Piper Aircraft Co. v. Reyno, 454 U.S. 235, 260-61 (1981); see also Reynolds, supra note
45, at 1681-82, 1707. But see supra text accompanying note 18 (suggesting that deterrence to achieve
a safer product is not at issue but rather deterrence that could impede marketing a vaccine at all).
133. CASSELS, supra note 21, at 178. The author urges, however, that "the corporate form can
too easily be used to avoid taking financial responsibility for risks not consented to" and that this
problem "is acute in the case of multinational corporations." Id. He argues further that "[Tihe
principle of limited liability is an instrument of public policy and is ultimately justifiable only when
grounded in the public good." Id. at 210.
134. See supra notes 45-48 and accompanying text.
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against foreign firms that do not face the same danger.135 It also may impede
foreign investment, because a relatively low risk of significant damages may
play a role in attracting foreign business and stimulating a developing economy. 
13 6
Not least, if huge verdicts were permitted, a U.S. company could potentially be
forced into bankruptcy, and the United States might lose a valuable domestic
manufacturer. 1
37
C. POSSIBLE SOLUTIONS INVOLVING DIFFERENT
APPROACHES TO COMPENSATION
Clearly, the reasons to limit the scope of liability-and their accompanying
legal doctrines, such as forum non conveniens and the sanctity of corporate
form-carry substantial weight. Yet there is something deeply troubling about
the prospect of indigent people (and their families) throughout the world receiving
little or no compensation for injuries incurred as a result of receiving a defective
AIDS vaccine. It is not inconceivable that, out of millions of potential recipients,
thousands or possibly tens of thousands of innocent people could be harmed.
The United States itself, not just the drug companies for which it is the home
country, might suffer a damaging blow to its relations with other states if it
ignored a problem created by a vaccine developed in the United States.
One possibility for compensation, if an American drug company were so bold
as to invent, develop, test, produce, and distribute a vaccine from this country,
would be suit by injured foreigners in U.S. courts against that company-subject,
at a minimum, to any limitations on damages that might apply to U.S. citizens. 138
Presumably, it would be more difficult to apply the doctrine of forum non conve-
niens if all decisions and most actions in the production and distribution of the
vaccine took place in the United States, even if administration of the vaccine
and injury occurred overseas. 39
In a much more likely scenario, the U.S. company would be the parent of a
foreign subsidiary (possibly incorporated and having its principal place of business
135. Birnbaum & Dunham, supra note 38, at 264 n. 107 (citing Besharov, Whose Law Should
Apply for Foreign Torts, NAT'L L.J., July 20, 1987, at 30)).
136. Reynolds, supra note 45, at 1708. The author also mentions that, if an American court were
to award damages many times higher than would be awarded by a foreign court, the policies of the
foreign courts' country would be disrupted. Id.
137. The legal actions against Dow Corning Corp., including claims by foreign plaintiffs, com-
pelled the company to file for bankruptcy. See supra note 48.
138. Wilson, supra note 17. Compensation to U.S. citizens for injury caused by an AIDS vaccine
should be determined through provisions similar to those found in the National Childhood Vaccine
Injury Act of 1986, Pub. L. 99-660, 100 Stat. 3755 (1986) (codified at 42 U.S.C. §§ 300aa-I to
-34 (1988)) and damages capped at $250,000. Id. at 562-66.
139. See In Re Air Crash Disaster, 531 F. Supp. 1175 (1982); see also supra note 86. Abuses
can occur, however, that would not necessarily be the fault of the pharmaceutical company, e.g.,
drugs approved by a foreign government for marketing that are dispensed without adequate warnings.
Pirt, supra note 15, at 273-74.
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in the host country) that would be responsible for production and distribution of
the vaccine. In this situation, an injured vaccine recipient might feel constrained
to bring suit in the host country under host country law against the subsidiary,
which might have been thinly capitalized and thus have little in the way of re-
sources to compensate victims. 1'4 In order to avoid this possibility, lawyers for
injured vaccinees might attempt to bring suit directly against the parent corpora-
tion on a theory of multinational-enterprise liability, as India did against Union
Carbide Corporation in the case of the Bhopal disaster.14 ' Although that case in
the United States was dismissed on forum non conveniens grounds, thus returning
it to India and the Indian legal system, the U.S. court implicitly accepted the
enterprise liability theory of the Indian government by requiring Union Carbide
to submit to the jurisdiction of the courts of India, 42 and it did so despite the
fact that the parent American corporation owned only 50.9 percent of its Indian
subsidiary. 143 It should be said, however, that Union Carbide exercised significant
control over the finances and management of its Indian operation, despite the
dilution of its ownership, and there was an overlapping board of directors.'"
For injured citizens of a foreign country, suits in the host country against a
subsidiary or its parent may bring relief, particularly if there are many plaintiffs
to force a settlement, but such suits have significant drawbacks. The process is
thereby legalized, with the attendant potential for delay, uneven judicial experi-
ence with suits of this nature, and the exclusion of many potentially deserving
plaintiffs who simply cannot afford the costs and fees that a lawsuit entails. 4
A potential solution to this dilemma might be an administrative claims process
established on a country-by-country basis. In this approach, a pharmaceutical
company marketing an AIDS vaccine would contract directly with a foreign
government wishing to distribute the vaccine to its citizens. The government
140. "[I]n industries involving hazardous processes and materials, there is strong evidence that
operations have been fragmented and segregated into smaller, thinly capitalized corporations in an
effort to avoid liability." CASSELS, supra note 21, at 178 (citing A. Ringleb & S. Wiggins, "Liability
and Large-Scale, Long-Term Hazards, 98 J. POL. EcON. 574 (1990)). "When a disaster does occur,
the assets and insurance of the local company are insufficient to compensate the victims, while the
assets of the parent are shielded from any claim." Id. at 178.
141. Id. at 179-80. The "duty would not depend upon vicarious liability or 'piercing the corporate
veil,' " although these concepts were argued, "but would be based on the concept that [the parent]
committed a wrong, independent of any ... tort committed by [the subsidiary] or its employees."
Id.
142. In re Union Carbide Corp. Gas Plant Disaster, 634 F. Supp. at 867; see also supra notes
97-99 and accompanying text; Obligations of a Company Belonging to an International Group, supra
note 35.
143. CASSELS, supra note 21, at 13, 181.
144. Id. at 182, 210. In the context of U.S. law, there was a sufficient connection between the
defendant and the forum state to find the minimum contact necessary for jurisdiction. Asahi Metal
Indus. Co. v. Superior Ct., 480 U.S. 102, 112 (1987).
145. As stated previously, companies fight hard for forum non conveniens dismissals because,
in most cases, such dismissals effectively end the legal proceedings. See supra note 75 and accompa-
nying text.
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might-or might not-mandate universal administration of the vaccine to its citi-
zens and the optimum ways to achieve whatever number of vaccinations it might
choose. Its decision would be based upon its own assessment of need, the delivery
vehicles available, and the characteristics of its population. It would be responsible
for informed consent, thereby eliminating the difficulty of securing individual
consent.146 If the government lacked resources and trained personnel to test ade-
quately for safety and efficacy, U.S. export controls would presumably ensure
equivalent safety in home and host countries.147
An important section of the contract would require the contracting government
to waive the legal liability of the pharmaceutical company in favor of the adminis-
trative claims procedure. This procedure, perhaps similar to workers' compensa-
tion, could be established to provide exclusive redress to its citizens for injuries. 1 48
In effect, the contract would provide that the host state would be the "choice
of forum" and its substantive law and procedure would be the "choice of law."
Litigation would be avoided, because liability would be without fault.' 49 As with
workers' compensation, the issues to be resolved would be inclusion within the
covered class (for example, was the claimant a vaccine recipient?), causation
(for example, did injury result from administration of a vaccine?), and the level
of each injured person's compensation.1'5 The latter could be regulated through
resort to schedules providing payment based upon the extent and duration of
illness or injury. 5' Administrators of the claims process would be host country
personnel, possibly trained by the drug company, who would acquire considerable
experience in assessing causation and who, in establishing payment schedules,
would undoubtedly be familiar with appropriate amounts of compensation in
light of prevailing wages, the general standard of living, and the social services
available in the country. 152 Because a remedy would be afforded, it seems highly
146. While individual informed consent is generally required, mandatory, government-ordered
vaccinations can override individual refusal. Jacobson v. Massachusetts, 197 U.S. 11 (1905).
147. See supra notes 22-24 and accompanying text. Admittedly, a perception of imperialism could
arise in this context, but it would be unlikely to prevail in the face of urgent need. See CASSELS,
supra note 21, at 281.
148. Id. at 253-55 & 278; see Louis Lasagna, The Chilling Effect of Product Liability on New
Drug Development, in THE LIABILITY MAZE 334, 348-53 (Peter W. Huber & Robert E. Litan eds.,
1991).
149. ARTHUR LARSON, WORKERS' COMPENSATION LAW 1, 3 (1992); JACK B. HOOD ET AL.,
WORKERS' COMPENSATION AND EMPLOYEE PROTECTION LAWS 58 (1990).
150. HOOD, supra note 149, at 59-60 (did injury arise out of or in the scope of employment?),
68-69, 84-85 (determining causation when a preexisting condition or outside influence may be pres-
ent), 100-04 (kinds of disabilities covered and compensation for each). LARSON, supra note 149, at
29-34, 101-02, 402-04, 557; see also CASSELS, supra note 21, at 261-62.
151. HOOD, supra note 149, at 99-109; LARSON, supra note 149, at 402-04; see also National
Childhood Vaccine Injury Act of 1986, supra note 138, 42 U.S.C. §§ 300aa-10(a), -1l(a)(2)(A),
-14(a).
152. An administrative rather than judicial process would be preferable. HOOD, supra note 149,
at 111-12, 115-17. The windfall that a foreign plaintiff might receive in U.S. courts would be avoided;
see supra notes 47-49 and accompanying text; see also BoRN & WESTIN, supra note 39, at 289.
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unlikely that in most cases U.S. courts would not defer to this process on forum
non conveniens grounds.
Payments would be made from a fund set up through contributions from both
the government and the drug company. 53 Most likely the industry contribution
would be small, as it would be based upon a percentage of the price of each dose
of vaccine, and for a vaccine to be feasible, the unit cost should be low. The
government contribution would be larger, and realistically, in view of the fact
that many impoverished nations could ill afford to both buy a vaccine and make
contributions to an injury compensation fund, the money would have to be pro-
vided through foreign and/or private international relief organizations."" As an
incentive to proper corporate conduct, the drug company might, after a term of
years, be permitted to recoup any unused portion of its contribution (unless its
contribution were provided in the form of insurance).
Would a drug company be interested in an administrative claims procedure
and thus induced to make an AIDS vaccine available in less developed areas of
the world? The answer is probably yes, because it would then be in the company's
financial interest to develop a vaccine. Avoidance of the hazards and expense
of litigation, even if the outcome of such litigation would usually be favorable to
a corporate defendant, would militate in favor of implementing an administrative
claims mechanism. At the same time, it must be recognized that this administrative
process might not comport with the legal system or societal values of a potential
recipient nation. Moreover, even if implemented, there would still be risks that
might not alleviate the fears of company counsel. Any procedure in the hands
of foreign personnel would have to be scrutinized carefully in view of the graft,
inefficiency, mismanagement, and corruption that exist in many countries of the
world. A compensation procedure might be mismanaged to a degree that would
be unacceptable. Of potentially greater significance, the possibility remains that
injured citizens of a foreign country, not bound by the contract to which their
government would be a party, would bring suit in tort in the United States where
corporate fear of substantial damages is the greatest. 155 A U.S. court would
probably dismiss on forum non conveniens grounds, particularly if the plaintiff's
country had established a mechanism for compensation. But that result would
not be foreordained, and it is at least conceivable that a U.S. court would retain
jurisdiction if, for example, manufacturing or design defects, or manifest failure
to warn, took place in this country. 1
6
153. CASSELS, supra note 21, at 258-59; see also 26 U.S.C. § 4131(a)-(b) (1988).
154. "The United States government could promote interest by the pharmaceutical industry in
the market in developing countries by making certain that a sufficient percentage of the United States'
foreign aid money to the Third World is designated for the purpose of essential pharmaceuticals."
Pirt, supra note 15, at 279. Of course, the United Nations could also play a role in funding local
compensation programs.
155. See supra notes 17-18 and accompanying text.
156. See supra notes 84-87 and accompanying text.
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In the final analysis, therefore, the best solution would seem to be a treaty
between the United States and recipient nations that would provide a claims
process and a compensation fund for individuals injured by a vaccine. The terms
of the treaty would automatically displace contrary state law under the supremacy
clause and would obviate application of state or federal products liability actions
for vaccine-related illnesses or injuries. 157 The treaty could be negotiated bilater-
ally, but preferably would be a multilateral treaty designed to stimulate widespread
distribution of a vaccine by establishing a process to compensate injured vaccine
recipients adequately yet concomitantly set limitations on the liability of vaccine
manufacturers.
One possible approach under such a treaty might be to internationalize the
claims process by establishing a UN-sponsored tribunal administered, perhaps,
by the World Health Organization. 158 Such a plan would require the creation
of an international bureaucracy to assess the validity of claims and the extent
of damages. Payments would be from a fund established through foreign aid
and industry contributions. Of course, a drawback would be the understandable
fear that a remote officialdom would lack the understanding to distribute funds
equitably for lost income, medical costs, and family support to individuals in
vastly different regions of the world. Moreover, the establishment of such a
centralized enterprise could raise fears of bureaucratic inefficiency on the part
of nations donating foreign aid; at the same time, it might also raise suspicions
of renewed imperialism in less-developed recipient countries, because the
organization would undoubtedly be substantially influenced by the policies of
the major donor nations. 159
In addition to the above-mentioned concerns, it would be difficult to reconcile
the use of a central, international claims tribunal with the retention of separate
claims procedures in each signatory nation, although suits between parties of the
same nationality might be exempted from the treaty provisions. Suits by U.S.
citizens for injuries sustained from an AIDS vaccine manufactured by a foreign
company would have to be referred to an international agency for resolution by
a cadre of international claims adjusters. Politically, therefore, the passage of a
treaty denying in-country relief, at least in the major donor nations, seems highly
unlikely. A possible solution would be to allow countries to enroll in an interna-
tional injury compensation process at each one's election, and manufacturers
could decline to make their products available in those nations that refuse both
to enroll and to prohibit the administration of the vaccine to nonnationals. Here
also, however, there would appear to be strong equal protection objections when
157. U.S. CONST. art. VI; United States v. Pink, 315 U.S. 203, 230 (1942); Amaya v. Standard
Oil & Gas Co., 158 F.2d 554, 556, cert. denied, 331 U.S. 808 (1946).
158. Such an arrangement through the World Health Organization has never yet been implemented
in practice.
159. See CASSELS, supra note 21, at 274, 281.
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countries of the less-developed world, even if by apparent choice, are effectively
forced into a system that nations of the developed world could most likely avoid.
To avoid these difficulties, perhaps the best solution would be to abandon a
centralized international agency approach and simply provide by treaty that each
signatory nation (a) forbid relief to citizens of other treaty states for vaccine-
related illnesses or injuries that were caused elsewhere, and (b) establish its own
procedures for compensating its citizens and others, regardless of the nationality
of the manufacturer, whenever an injury from the administration of an AIDS
vaccine occurs within its borders. The treaty could also require its adherents not
to make an AIDS vaccine available to any person from a nonsignatory state,
thereby avoiding the minor, but potentially vexing, problem of a foreigner receiv-
ing a vaccine and then initiating a lawsuit for resulting injury either at home or
overseas. However, if citizens of signatory nations are inoculated in a signatory
state that is not their place of residence, they or their personal representatives
could be given the opportunity to seek redress within their home states if compen-
sation would be determined more appropriately in the place of residence.6o Thus,
the claim of each victim would be adjudicated by, and payment made according
to, the legal processes and governing law of the place where personal injury
occurred or where that person resides. Suit in another jurisdiction, in an attempt
to apply foreign law, would be forbidden, and consequently, resort to forum non
conveniens, or to the resolution of difficult choice of law questions, would cease.
This approach would leave open the previously described possibility of work-
ers' compensation-type schemes to limit liability.1 6 ' As already mentioned, a
160. In the overwhelming number of cases, of course, the place of injury will also be the place
of residence. Much evidence, e.g., testimony by those administering or storing a vaccine, will be
available at this location. But damages in the form of lost wages and the cost of medical treatment
may be most appropriately determined at the place of new or habitual residence; for example, an
American working and vaccinated overseas, but planning to return to the United States, might find
an award in a foreign country far below his or her anticipated standard of living. In such cases,
moreover, the domicile of a plaintiff has an interest in providing compensation to avoid having him
or her become a public charge. WEINTRAUB, supra note 116, at 307. Thus, a plaintiff who changes
residence should be permitted to bring suit in either the new state of residence or the state of injury.
Id. at 345-49, 351-52 (citing, by analogy, the Convention on the Law Applicable to Products Liability,
III Acts and Documents of the 12th Session of the Hague Conference on Private International Law
(1972), reprinted in 21 AM. J. CoMP. L. 150 (1973), and the proposal of David Cavers, The Proper
Law of Producer's Liability, 26 INT'L & Comp. L.Q. 703, 728-29 (1977)), and id. at 355 (where,
among other proposals, the author would permit a plaintiff to choose the law of his or her habitual
residence or the law of the place where a product is acquired, if distribution through commercial
channels in that location is foreseeable); see also Exchange of Letters Constituting an Agreement
Concerning the Judicial System in the New Hebrides and Amending the Above-Mentioned Agreement,
as Amended, London, 1978, Treaty Series, vol. 1135, United Nations, New York (1990), at 464.
Treaty of Friendship, Commerce and Navigation between the United States of America and Japan,
arts. 1I-IV, § 1, 4 U.S.T. 2063, T.I.A.S. No. 2863 (Apr. 2, 1953) (granting nationals of either
party national treatment with respect to access to courts and administrative tribunals and application
of law within the territories of the other party).
161. See supra notes 148-51 and accompanying text. A workers' compensation scheme might,
in fact, be built into the treaty, including its foreign aid provisions, as an inducement to join.
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procedure of this sort would avoid costly and time-consuming litigation in the
host country, and the threat of extraterritorial litigation would be eliminated if
a treaty prohibited legal action outside the country of injury or of residence.
Creation of this kind of administrative process would be encouraged, because
pharmaceutical corporations, while free to sell their products wherever possible
throughout the world, could nevertheless refuse to do business in any country
whose internal legal processes might lead to onerous liability. Decision making
would take place on a country-by-country and company-by-company basis,
thereby ensuring maximum flexibility and sensitivity to each country's and com-
pany's unique conditions and needs.
Under any scheme that restricts injured vaccinees to redress in, and according
to the laws of, their own less-developed countries, inadequate compensation is
a very real threat. Impoverished nations may well lack the resources to provide
assistance to their own people. In the workers' compensation approach described
above,'62 a combination of foreign aid and a premium on the selling price are
envisaged as sources of money for compensation funds. Earmarked foreign aid
from the wealthy countries of the world will have to underwrite a global inocula-
tion effort. Admittedly, there is no guarantee that such aid will be forthcoming,
but certainly money will be needed either to allow recipient nations to compensate
their citizens directly or to assist recipient nations in the purchase of vaccines
so that those companies selling vaccines can contribute a certain percentage of
the purchase price to a fund for injured victims.
IV. Conclusion
The need for a vaccine to stem the disease of AIDS throughout the world is
imperative. 163 But all medical procedures entail some degree of risk, and impover-
ished foreigners, injured by administration of a vaccine developed in the United
States, will attempt to take advantage of the lenient legal processes and high
damage awards potentially available in this country."6 American corporations
have resorted to the doctrine of forum non conveniens and the creation of foreign
subsidiaries to avoid liability to foreign nationals. 65 To the extent these techniques
work-and they usually do-they may leave injured foreigners without just com-
pensation; however, without legal protection, most companies are unwilling to
do business in the less-developed world.66 This article proposes passage of a
multilateral treaty under the terms of which each contracting state would be
limited to adjudicating compensation solely for the vaccine-related injuries of its
citizens, or others who receive the vaccine within its borders, according to its
162. Id.
163. See supra notes 1-11 and accompanying text.
164. See supra notes 41-45 and accompanying text.
165. See supra notes 50-101 and accompanying text.
166. See supra notes 134-37 and accompanying text.
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own domestic law and legal processes. This article further proposes that, under
such a treaty, as an inducement to foreign vaccine manufacturers, each country
that desires an AIDS vaccine waive tort liability in favor of an administrative
process similar to workers' compensation. This process would include a compen-
sation fund, established by contributions from both the host government and the
pharmaceutical company selling the AIDS vaccine, to handle claims on a no-fault
basis from people who claim to have been injured by the vaccine. 167 The funding
for the pharmaceutical company's contribution would come from a slight increase
in the unit price of each dose of vaccine that is sold, whereas the host government's
contribution may be provided largely by the international community. 168 Because
AIDS is an international problem, an international response is clearly justified.
167. See supra notes 148-51 and accompanying text.
168. See supra notes 153-54, 162 and accompanying text.
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